Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06469658 Completed - Diabetes Clinical Trials

Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation

Start date: February 2, 2024
Phase: N/A
Study type: Interventional

This randomized controlled trial investigates the effectiveness of AI-guided dietary supplement prescriptions compared to standard physician-guided prescriptions in managing Type 2 diabetes (T2D). The study includes 160 participants with T2D, aged 40-75, who will be randomly assigned to either the control group (standard physician-guided prescriptions) or the AI-guided group (prescriptions determined by GenAIS, an AI system by Triangel Scientific). The primary objective is to compare the reduction in HbA1c levels between the two groups over 6 months. Secondary outcomes include changes in fasting glucose, lipid profiles, body weight, BMI, hsCRP levels, and adherence to the dietary supplement regimen. The AI system integrates genetic, metabolic, and clinical data to provide personalized supplement recommendations, aiming to improve glycemic control and overall metabolic health.

NCT ID: NCT06468371 Completed - Hemodialysis Clinical Trials

Exercise Training Versus Ropinirole in Treating Restless Legs Syndrome Among Hemodialysis Patients

Start date: January 2, 2022
Phase: N/A
Study type: Interventional

This research aims to compare the efficacy of these two interventions, thereby addressing a critical gap in current therapeutic approaches. The rationale for this study is rooted in the existing evidence supporting non-pharmacological and pharmacological interventions for RLS, yet the comparative efficacy remains underexplored.

NCT ID: NCT06463535 Completed - Diabetes Mellitus Clinical Trials

Effects of Omega-3 as an Adjunct to Non-Surgical Periodontal Therapy on Chemerin Level in Periodontitis Patients With Diabetes: A Randomized Clinical Trial

Start date: June 15, 2023
Phase: N/A
Study type: Interventional

Patient grouping - Group 1 (Type 2 Diabetes Mellitus patients with CPD + SRP and Omega-3) - Group 2 (Type 2 Diabetes Mellitus patients with CPD + SRP) different clinical parameters were recorded ; plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment loss (CAL). 6.Omega-3 poly-unsaturated fatty acids (1000mg) was given as an adjunctive treatment daily for 6 months to group 2, starting 2 weeks after phase 1 therapy.

NCT ID: NCT06461871 Completed - Clinical trials for Diabetes Mellitus, Type 2

Combined Effects of BT With Moderate Intensity Aerobic Versus RT in Type 2 DM.

Start date: June 10, 2023
Phase: N/A
Study type: Interventional

A randomized control trail will be conducted at Social Security Teaching Hospital, Multan Road, Lahore. Social Security Teaching Hospital Shah rah, Lahore. Non -probability Convenient Random Sampling Technique will be applied on patients who will be allocated through simple random sampling into group A and group B. Group A received moderate intensity aerobic exercises which include walking, cycling, with each session lasting 15 minutes for 3-5 days per week in combination with balance training which include heel raise, standing march with 10 repetitions each for 3-5 days per week. Group B receive moderate intensity resistance exercises which include biceps curls, triceps curls , with each session lasting 10 repetitions for 3-5 days per week in combination with balance training which include heel raise, standing march with 10 repetitions each for 3-5 days per week. The study will be completed with time duration of six months .Primary outcome of research will be glycemic control, cardio respiratory fitness, and quality of life. Data will be analyzed using SPSS software version 21. After assessing normality of Shapiro-will test, it will be decided either parametric or non parametric test will be used within a group or between groups.

NCT ID: NCT06444334 Completed - Diabetes Clinical Trials

Laser Biostimulation on Implant Covered With PRF in Controlled Diabetics

PRF
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

the goal of this clinical trial is to evaluate laser biostimulation effect on osseointegration of implant covered by PRF(platelet rich fibrin) in controlled diabetic patients with compromised healing potential. METHODS: The study was conducted on type 2 controlled diabetic patients receiving 22 implants covered with PRF inserted in posterior maxilla or mandible. Implants were divided randomly into 2 groups. Group1: control group (received no laser irradiation), group2: received diode laser. Peri-implant new bone density and secondary stability were assessed using cone-beam computed tomography and Anycheck device respectively. Density was evaluated immediately post implant insertion and after 5 months, while implant stability was performed 5 months post implant insertion. Statistical analysis was executed significance level P ≤ 0.05.

NCT ID: NCT06436001 Completed - Diabetes Mellitus Clinical Trials

Comparing BlueDop Vascular Expert to Ankle-Brachial Index in the Identification of Peripheral Vascular Disease

Start date: March 1, 2023
Phase:
Study type: Observational

To compare the screening capabilities of the BlueDop Vascular Expert (BVE) and ankle brachial index (ABI) in peripheral arterial disease for all-comer patients and those with diagnosed diabetes mellitus.

NCT ID: NCT06435130 Completed - Obesity Clinical Trials

The Impact of Chokeberry Bioproducts on Metabolic Parameters and Antioxidant Potential

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Chokeberry can be used both in the prevention and treatment of various metabolic disorders due to its high antioxidant properties. The study assessed for the first time the synergistic effect of chokeberry juice and chokeberry fiber on selected metabolic and anthropometric parameters. 102 people (67 women and 35 men) took part in the intervention study. After 8 weeks of intervention with chokeberry juice and another 4 weeks of intervention with chokeberry juice and fiber, a change in waist circumference, blood pressure, glucose, glycated hemoglobin, LDL cholesterol, aspartate transaminase (AST) and the level of antioxidant potential was observed.

NCT ID: NCT06434584 Completed - Diabetes Clinical Trials

Explainable Insulin Decision-making System to Assist Physicians in Diabetes Management

Start date: December 10, 2022
Phase:
Study type: Observational

The investigators plan to conduct a multi-case, multi-reader observational study with the primary objective of exploring the effects of an interpretable insulin-assisted decision-making system on physicians' (1) decision accuracy and (2) decision confidence.

NCT ID: NCT06428591 Completed - Clinical trials for Diabetes Mellitus, Type 1

Tandem Freedom - Feasibility Trial 1

Start date: May 29, 2024
Phase: N/A
Study type: Interventional

This feasibility study is a prospective, single arm study evaluating the Tandem Freedom system in adults with type 1 diabetes. Existing Control-IQ technology users will use Control-IQ technology at home for a 1 week run-in, then will use Tandem Freedom in a supervised hotel setting for 3 days/nights.

NCT ID: NCT06426966 Completed - Obesity Clinical Trials

Gymnema Sylvestre vs Berberine in Obesity Gene Expression of Adipokines

GS VS BBR A
Start date: February 1, 2016
Phase: N/A
Study type: Interventional

Obesity is a disease that affects a large part of the world's population and is a risk factor for the development of metabolic, cardiovascular, oncological, and neurodegenerative diseases. Treatments with Gymnema Sylvestre (GS) and Berberine (BBR) have been studied in metabolic diseases such as obesity and type 2 diabetes mellitus (DM2), and have gained importance in recent years, however, questions remain regarding their comparative effect on biochemical parameters, body composition and gene expression of adipokines. Methodology. We carried out a comparative study in 50 adult Mexican patients with a diagnosis of Obesity. Two groups of patients were formed: A. Treated with GS and B. Treated with BBR. Baseline and final measurements were determined 3 months after treatment. Biochemical and body composition parameters were evaluated and the gene expression of Resistin (Res), Omentin (Om), Visfatin (Vis) and Apelin (Ap) was determined, as well as safety parameters.